Bringing together members of academia, allied health professionals, clinicians, industry and government.

Latest News Find out more

Portfolio Projects in Wales

Welsh Stroke Portfolio Studies – All

 

Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Evaluating an extended rehabilitation service for stroke patients The EXTRAS trial aims to determine the clinical and cost effectiveness of an extended stroke rehabilitation service. Stroke patients and carers who agreed to participate in the trial were randomly allocated to either receive a new extended stroke rehabilitation service or to continue with usual NHS care.  The effectiveness of the new extended rehabilitation service will be evaluated by comparing the health of patients and carers who received the new service with those who received usual NHS care.
For more information please visit,
https://research.ncl.ac.uk/extrastrial/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
HeadPoST Version 2.1
Head Position in Stroke Trial
This study is an investigator-initiated and conducted, international collaborative, regionally organised, multicentre, prospective, cluster randomised, crossover, blinded outcome assessment study to compare the effectiveness of the lying flat (0°) head position with the sitting up (=30°) head position, in the first 24 hours of admission to hospital for patients with acute stroke, on the poor outcome of death or disability over the subsequent 90 days.
For more information please visit,
https://www.georgeinstitute.org/projects/head-position-in-stroke-trial-headpost
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
RIVER Registry – RIVaroxaban Evaluation in Real life setting To discover outcomes of patients treated with Rivaroxaban with atrial fibrillation with at least one additional investigator-determined risk factor for stroke in real-life practice. For more information please visit,
https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/river-registry-rivaroxaban-evaluation-in-real-life-setting/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Stroke Peer Support and Coaching Waiting for information ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
FOCUS
The effect (s) of routine administration of Fluoxetine in patients with a recent stroke
The FOCUS trial is aims to establish whether a six month course of fluoxetine, started within the first 15 days after an acute stroke, improves patients recovery over the first year. Also whether the treatment is cost effective (i.e. that any costs associated with the treatment are offset by health gains, and or reductions in healthcare and social care costs. This research aims to improve the care received by NHS patients and the use of NHS resources. Recruitment to the trial closed on the 31st March 2017. 3127 participants were recruited to the trial. The final patient and GP follow-ups for the patients recruited on the 31st March 2017 are due on 31st March 2018.
For more information please visit,
http://www.focustrial.org.uk/default.html cl.ac.uk/extrastrial/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
TICH2
Tranexamic acid for IntraCerebral Haemorrhage
When someone has a stroke caused by bleeding into the brain (haemorrhagic stroke) permanent brain damage can occur and result in long-term disability. There is also a chance that the bleeding can increase, which may cause worse disability or be life threatening. This happens in approximately 20-30% of haemorrhagic stroke patients. At present there is no available treatment that is effective at reducing the bleeding in the brain and improving the recovery. In this trial, we want to test whether it is possible to give a drug (tranexamic acid) to people in the first few hours after a haemorrhagic stroke. We hope that we will be able to show that giving the drug may reduce the chances of dying and being left with disability after a haemorrhagic stroke. In this trial, the treatment we are testing is a drug, tranexamic acid, which encourages blood to clot to stop the bleeding. Continued or increased bleeding into the brain (haematoma expansion) is not uncommon in the first hours and days following a haemorrhagic stroke and increases the risk of the patient not recovering fully and being left with some disability. Stopping the bleeding in the first hours and days after stroke with medicine might help patients to recover better. Tranexamic acid is a tried and tested drug in other medical conditions that acts quickly to help the blood to clot and stop bleeding but is not given routinely after stroke. The aim of this study is to assess what effect tranexamic acid has on how people recover after a haemorrhagic stroke.
For more information please visit http://tich-2.org/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
BIG CACTUS A study to assess the clinical cost effectiveness of aphasia computer treatment versus usual stimulation or attention control long term post stroke (CACTUS)
For more information please visit,https://www.sheffield.ac.uk/scharr/sections/dts/ctru/bigcactus
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
RESTART Restart or stop antithrombotics randomised trial. Restart or stop antithrombotics randomised trial. For adults surviving spontaneous (non-traumatic) intracerebral haemorrhage (ICH) who had taken and antithrombotic (ie anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease before ICH, does a policy of starting antiplatelet therapy result in a beneficial net reduction of all serious vascular events over two years compared with a policy of avoiding antiplatelet therapy?
For more information please visit,
http://restarttrial.org/default.html
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
LoTS2Care
A longer-term care strategy for stroke – a feasibility study
This feasibility study is the 5th of five work streams funded by an NIHR Programme Grant to develop and evaluate key aspects of a replicable system of longer-term service delivery ‘care strategy’. The emphasis is on improving quality of life by addressing unmet needs and enhancing participation. In previous workstreams, work has focused on development of an intervention, to be delivered by community-based staff, called ‘New Start’
For more information please visit,
https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/longer-term-support-for-stroke-survivors-and-their-carers/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Neurofeedback for functional motor recovery after stroke. Waiting on information ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
ENCHANTED Enhanced Control of Hypertension and Thrombolysis Stroke Study ENCHANTED is an independent, investigator initiated, international collaborative, quasi-factorial randomised controlled trial involving a package of 2 linked comparative randomised treatment arms, which aims to address 4 key questions in patients eligible for thrombolysis in the acute phase of ischaemic stroke. (1) Does low-dose (0.6 mg/kg) intravenous (i.v.) recombinant tissue plasminogen activator (rtPA) provide equivalent benefits compared to standard-dose (0.9 mg/kg) rtPA? (2) Does intensive blood pressure (BP) lowering (130-140 mmHg systolic target) improve outcomes compared to the current guideline recommended level of BP control (180 mmHg systolic target)? (3) Does low-dose (0.6 mg/kg) intravenous (i.v.) recombinant tissue plasminogen activator (rtPA) reduce the risk of symptomatic intracerebral haemorrhage (sICH)? (4) Does the addition of intensive BP lowering to thrombolysis with rtPA reduce the risk of any intracerebral haemorrhage (ICH)?
For more information please visit,
https://clinicaltrials.gov/ct2/show/NCT01422616
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST

Key
ABMUHB – Abertawe Bro Morgannwg University Health Board
ABUHB – Aneurin Bevan University Health Board
BCUHB – Betsi Cadwaladr University Health Board
CAVUHB – Cardiff and Vale University Health Board
CTUHB –Cwm Taf University Health Board
HDHB – Hywel Dda Health Board
PTHB – Powys Teaching Health Board
WAST – Welsh Ambulance Service Trust

Welsh Stroke Portfolio Studies (Closed)

 

Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Evaluating an extended rehabilitation service for stroke patients The EXTRAS trial aims to determine the clinical and cost effectiveness of an extended stroke rehabilitation service. Stroke patients and carers who agreed to participate in the trial were randomly allocated to either receive a new extended stroke rehabilitation service or to continue with usual NHS care.  The effectiveness of the new extended rehabilitation service will be evaluated by comparing the health of patients and carers who received the new service with those who received usual NHS care.
For more information please visit,
https://research.ncl.ac.uk/extrastrial/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
HeadPoST Version 2.1
Head Position in Stroke Trial
This study is an investigator-initiated and conducted, international collaborative, regionally organised, multicentre, prospective, cluster randomised, crossover, blinded outcome assessment study to compare the effectiveness of the lying flat (0°) head position with the sitting up (=30°) head position, in the first 24 hours of admission to hospital for patients with acute stroke, on the poor outcome of death or disability over the subsequent 90 days.
For more information please visit,
https://www.georgeinstitute.org/projects/head-position-in-stroke-trial-headpost
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
RIVER Registry – RIVaroxaban Evaluation in Real life setting To discover outcomes of patients treated with Rivaroxaban with atrial fibrillation with at least one additional investigator-determined risk factor for stroke in real-life practice. For more information please visit,
https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/river-registry-rivaroxaban-evaluation-in-real-life-setting/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Stroke Peer Support and Coaching Waiting for information ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
FOCUS
The effect (s) of routine administration of Fluoxetine in patients with a recent stroke
The FOCUS trial is aims to establish whether a six month course of fluoxetine, started within the first 15 days after an acute stroke, improves patients recovery over the first year. Also whether the treatment is cost effective (i.e. that any costs associated with the treatment are offset by health gains, and or reductions in healthcare and social care costs. This research aims to improve the care received by NHS patients and the use of NHS resources. Recruitment to the trial closed on the 31st March 2017. 3127 participants were recruited to the trial. The final patient and GP follow-ups for the patients recruited on the 31st March 2017 are due on 31st March 2018.
For more information please visit,
http://www.focustrial.org.uk/default.html cl.ac.uk/extrastrial/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
TICH2
Tranexamic acid for IntraCerebral Haemorrhage
When someone has a stroke caused by bleeding into the brain (haemorrhagic stroke) permanent brain damage can occur and result in long-term disability. There is also a chance that the bleeding can increase, which may cause worse disability or be life threatening. This happens in approximately 20-30% of haemorrhagic stroke patients. At present there is no available treatment that is effective at reducing the bleeding in the brain and improving the recovery. In this trial, we want to test whether it is possible to give a drug (tranexamic acid) to people in the first few hours after a haemorrhagic stroke. We hope that we will be able to show that giving the drug may reduce the chances of dying and being left with disability after a haemorrhagic stroke. In this trial, the treatment we are testing is a drug, tranexamic acid, which encourages blood to clot to stop the bleeding. Continued or increased bleeding into the brain (haematoma expansion) is not uncommon in the first hours and days following a haemorrhagic stroke and increases the risk of the patient not recovering fully and being left with some disability. Stopping the bleeding in the first hours and days after stroke with medicine might help patients to recover better. Tranexamic acid is a tried and tested drug in other medical conditions that acts quickly to help the blood to clot and stop bleeding but is not given routinely after stroke. The aim of this study is to assess what effect tranexamic acid has on how people recover after a haemorrhagic stroke.
For more information please visit http://tich-2.org/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
BIG CACTUS A study to assess the clinical cost effectiveness of aphasia computer treatment versus usual stimulation or attention control long term post stroke (CACTUS)
For more information please visit,https://www.sheffield.ac.uk/scharr/sections/dts/ctru/bigcactus
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
RESTART Restart or stop antithrombotics randomised trial. Restart or stop antithrombotics randomised trial. For adults surviving spontaneous (non-traumatic) intracerebral haemorrhage (ICH) who had taken and antithrombotic (ie anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease before ICH, does a policy of starting antiplatelet therapy result in a beneficial net reduction of all serious vascular events over two years compared with a policy of avoiding antiplatelet therapy?
For more information please visit,
http://restarttrial.org/default.html
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
LoTS2Care
A longer-term care strategy for stroke – a feasibility study
This feasibility study is the 5th of five work streams funded by an NIHR Programme Grant to develop and evaluate key aspects of a replicable system of longer-term service delivery ‘care strategy’. The emphasis is on improving quality of life by addressing unmet needs and enhancing participation. In previous workstreams, work has focused on development of an intervention, to be delivered by community-based staff, called ‘New Start’
For more information please visit,
https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/longer-term-support-for-stroke-survivors-and-their-carers/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Neurofeedback for functional motor recovery after stroke. Waiting on information ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
ENCHANTED Enhanced Control of Hypertension and Thrombolysis Stroke Study ENCHANTED is an independent, investigator initiated, international collaborative, quasi-factorial randomised controlled trial involving a package of 2 linked comparative randomised treatment arms, which aims to address 4 key questions in patients eligible for thrombolysis in the acute phase of ischaemic stroke. (1) Does low-dose (0.6 mg/kg) intravenous (i.v.) recombinant tissue plasminogen activator (rtPA) provide equivalent benefits compared to standard-dose (0.9 mg/kg) rtPA? (2) Does intensive blood pressure (BP) lowering (130-140 mmHg systolic target) improve outcomes compared to the current guideline recommended level of BP control (180 mmHg systolic target)? (3) Does low-dose (0.6 mg/kg) intravenous (i.v.) recombinant tissue plasminogen activator (rtPA) reduce the risk of symptomatic intracerebral haemorrhage (sICH)? (4) Does the addition of intensive BP lowering to thrombolysis with rtPA reduce the risk of any intracerebral haemorrhage (ICH)?
For more information please visit,
https://clinicaltrials.gov/ct2/show/NCT01422616
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST

Key
ABMUHB – Abertawe Bro Morgannwg University Health Board
ABUHB – Aneurin Bevan University Health Board
BCUHB – Betsi Cadwaladr University Health Board
CAVUHB – Cardiff and Vale University Health Board
CTUHB –Cwm Taf University Health Board
HDHB – Hywel Dda Health Board
PTHB – Powys Teaching Health Board
WAST – Welsh Ambulance Service Trust

Welsh Stroke Portfolio Studies (Open)

 

Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
PASTA
Paramedic Acute Stroke Treatment Assessment
Paramedic Acute Stroke Treatment Assessment – This research study is a clinical trial to determine whether a Paramedic Acute Stroke Treatment Assessment (PASTA) pathway can speed up access to emergency stroke treatments, especially thrombolysis treatment, and so improve recovery after stroke. Participants receive either usual emergency stroke care or the additional PASTA pathway.
For more information please visit,
https://research.ncl.ac.uk/pasta/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
RIGHT-2 Rapid intervention with glyceryl trinitrate in hypertensive stroke trial Rapid intervention with glyceryl trinitrate in hypertensive stroke trial – assessment of safety and efficacy of transdermal GTN, and the feasibility of a multicentre ambulance-based stroke trial
For more information please visit,
http://right-2.ac.uk/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
STROLLERS
Stroke Life and Leisure Research Survey
Waiting for information ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
ELAN Early versus late initiation of direct oral anticoagulants in post-ischaemic stroke patients with non-valvular atrial fibrillation The ELAN trial aims to estimate the net benefit of early versus late (current standard practice) initiation of direct oral anticoagulants (DOACs) in patients with acute ischaemic stroke related to atrial fibrillation.
For more information please visit,https://www.elan-trial.ch/about-the-trial/
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
CONVINCECOichichine for preventioN of vascular Inflammation in Non-CardioEmbolic stroke This study evaluates the use of Colchicine in adults over 40 years of age who have suffered an ischaemic stroke or transient ischaemic attack NOT caused by cardiac embolism or other defined causes. Patients will be randomised to 0.5 mg/day of Colchicine plus usual care, or to usual care alone.
To investigate the efficacy of low dose colchicine (0.5mg/day) plus usual care (defined as antiplatelet, lipid-lowering, antihypertensive treatment, and appropriate lifestyle advice) compared with usual care alone to prevent non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, hospitalization for unstable angina and vascular death after ischaemic stroke or transient ischaemic attack (TIA) not caused by cardiac embolism or other defined causes unrelated to atherosclerosis
For more information please visit,https://clinicaltrials.gov/ct2/show/NCT02898610
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
PLORAS Predicting Language Outcome and Recovery After Stroke PLORAS is a research project looking at recovery of language difficulties after stroke (aphasia).
Aim: to give future stroke survivors a prediction about their aphasia recovery.
For more information please visit,
http://www.ucl.ac.uk/ploras
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
R4VAD Rate, risks and routes to reduce vascular dementia Waiting for information
For more information please visit,https://www.nottingham.ac.uk/research/groups/stroke/clinical-stroke-trials/index.aspx
ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Characterizing Clot Microstructure in Atrial Fibrillation and Stroke Stroke and Atrial fibrillation especially in South Wales are major diseases resulting in a significant social and economic burden. It has long been argued that AF and stroke unfavourably alter how the blood clots, however, there is no available test that can provide a numerical description of blood clotting quality in a clinical setting. The main goal of this observational study is to validate a novel test of clot quality, fractal dimension (df) in atrial fibrillation patients with and without stroke. This study aims to determine whether these patients are more likely to produce substantially modified clots that results in poorer clot quality and how these patients respond to anti coagulation (blood thinning) therapy. To do this a baseline blood sample will be taken for 2 different groups: atrial fibrillation patients suffering a stroke and atrial fibrillation patients without stroke. These patients will then receive oral anticoagulant therapy, following which a second sample will be taken to determine whether they improve clotting quality. The results of the second blood test will be compared to the results of their matched baseline for each participant to ascertain what effect oral anticoagulation has on clotting quality.

For more information please visit,
https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/characterizing-clot-microstructure-in-atrial-fibrillation-and-stroke/

ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Project Summary ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST
Delivery of Patient Reported Health Status Questions in Stroke A Patient Reported Outcome Measure (PROM) is a questionnaire that asks patients for their views on their own health or the impact of healthcare they have received on their health and quality of life\n\nThere is a PROM (the PROMIS-10 Global Health) and a number of extra questions that are recommended for use in people who have had a stroke by the International Consortium for Health Outcomes Measurement, but the best way of delivering these questions for stroke survivors is unknown.\n\nAt present, the NHS in England, Scotland and Wales are required to offer every stroke survivors a 6 month post stroke follow-up appointment. Currently, the information collected at this 6 month review is not from the patient’s perspective and the best method of collecting this information has not been established.\n\nThe aim of this research is to understand if there is a difference between 4 methods of administration using a grouping of Patient Reported Health Status Questions (PRHSQs) in people who have had a stroke. \n\nThe four methods of administration are: \n\n-\tFace-to-Face\n-\tTelephone\n-\tOnline\n-\tPost\nTo conduct this research study four initial Principal Investigators in 4 sites have agreed to take part. Aneurin Bevan Health Board will hold 3 sites and Cwm Taf University Health Board will hold 1 site. Between each site a sample of 808 eligible stroke survivors will be asked to take part. From these 808 people, 202 participants will be randomly assigned to each method of administration. \n\nThe study data collection will run concurrent from 1st June 2017 to 31st December 2017. \n\nThe conclusions of this research will inform the roll-out of the most appropriate method of delivering the 6 month stroke follow-up review for stroke survivors.

For more information please visit,
https://clinicaltrials.gov/ct2/show/NCT03177161

ABMUHB ABUHB BCUHB CAVUHB CTUHB HDHB PTHB WAST

Key
ABMUHB – Abertawe Bro Morgannwg University Health Board
ABUHB – Aneurin Bevan University Health Board
BCUHB – Betsi Cadwaladr University Health Board
CAVUHB – Cardiff and Vale University Health Board
CTUHB –Cwm Taf University Health Board
HDHB – Hywel Dda Health Board
PTHB – Powys Teaching Health Board
WAST – Welsh Ambulance Service Trust